Loading stock data…
XBIO
$3.08-0.01 (-0.23%)
Market ClosedLast close Jun 9
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xenetic Biosciences, Inc. in the Healthcare sector is trading at $3.08. The stock is currently near its 52-week low of $1.90, remaining 4.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.08
Potential Downside
0%
Whystock Fair Value$3.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.14%
Volume
Today's trading volume
6,044
Recent News
Xenetic Biosciences: Q4 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Thursday reported a loss of $579,000 in its fourth quarter.
Xenetic Biosciences: Q3 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Wednesday reported a loss of $510,000 in its third quarter.
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences: Q2 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Tuesday reported a loss of $689,000 in its second quarter.